Bausch + Lomb shares climb on earnings beat, raised outlook

May 1, 2024 · Bausch + Lomb shares climb on earnings beat, raised outlook Open in App ... Bausch + Lomb shares climb on earnings beat, raised outlook. Stock Markets. Published …

$0.13
OFF

Bausch + Lomb Posts Top-line Beat, Raises Full-year Outlook

2 weeks from now

Oct 30, 2024 · Bausch + Lomb posts top-line beat, raises full-year outlook ... Adjusted earnings per share came in at $0.13, missing analyst estimates of $0.16. ... Bausch + Lomb raised its …

investing.com

8%
OFF

Bausch + Lomb Third Quarter 2024 Earnings: Beats Expectations

2 weeks from now

Nov 1, 2024 · Bausch + Lomb Revenues and Earnings Beat Expectations. Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) also surpassed analyst estimates. …

yahoo.com

$4
OFF

Bausch + Lomb Turns To Q3 Profit; Raises Full-year Revenue Outlook

2 weeks from now

Oct 30, 2024 · (RTTNews) - Bausch + Lomb Corporation (BLCO), an eye health company, Wednesday reported net income of $4 million or $0.01 per share for the third quarter, …

nasdaq.com

9%
OFF

Bausch & Lomb’s Stock Soars 9% After Earnings Beat

2 weeks from now

Feb 21, 2024 · Bausch & Lomb Corp.’s stock soared 10% early Wednesday after the eye-care company reported adjusted fourth-quarter profit that topped estimates and offered upbeat …

marketwatch.com

8%
OFF

Bausch & Lomb Earnings: Broad-Based Growth And Margin

2 weeks from now

Oct 30, 2024 · Narrow-moat Bausch & Lomb reported solid third-quarter earnings that came in a tad higher than our expectations. Total sales of $1.2 billion were up 18.8% year over year …

morningstar.com

$4.73
OFF

Bausch + Lomb’s Strong Financial Performance And Strategic …

2 weeks from now

Oct 31, 2024 · Bausch + Lomb reports Q3 adjusted EPS 17c, consensus 22c Bausch + Lomb raises FY24 revenue view to $4.73B-$4.83B from $4.7B-$4.8B Bausch Health price target …

businessinsider.com

8%
OFF

Bausch + Lomb (BLCO) Q3 Earnings: Taking A Look At Key Metrics …

2 weeks from now

Oct 30, 2024 · For the quarter ended September 2024, Bausch + Lomb (BLCO) reported revenue of $1.2 billion, up 18.8% over the same period last year. EPS came in at $0.17, compared to …

nasdaq.com

10%
OFF

Bausch Health Q3 Earnings And Revenues Top, Xifaxan Boosts Sales

2 weeks from now

The company also raised its annual revenue guidance. Adjusted earnings per share of $1.12 beat the Zacks Consensus Estimate of $1.03. ... Bausch + Lomb’s revenues increased 10% …

yahoo.com

$0.17
OFF

Bausch + Lomb (BLCO) Q3 Earnings And Revenues Top Estimates

2 weeks from now

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.22 per share a year …

msn.com

$20
OFF

Bausch + Lomb Tops Profit Expectations, Provides In-line Revenue …

2 weeks from now

Jun 8, 2022 · Net income fell to $20 million, or 6 cents a share, from $27 million, or 8 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of 24 …

marketwatch.com

20%
OFF

Bausch & Lomb Shares Upgraded, Price Target Raised - Investing.com

2 weeks from now

Oct 15, 2024 · In other recent news, Bausch + Lomb has reported a robust 20% constant currency revenue growth in the second quarter of 2024, leading them to raise their full-year …

investing.com

11%
OFF

Bausch Health Shares Rise On FY Outlook Upgrade, 3Q Beat

2 weeks from now

Oct 31, 2024 · Bausch Health shares rose Thursday morning after the company raised its full year outlook following a better-than-expected third-quarter performance. Shares traded over 11% …

marketwatch.com

$1.12
OFF

Bausch Health Q3 Earnings And Revenues Top, Xifaxan Boosts Sales

2 weeks from now

Nov 1, 2024 · The company also raised its annual revenue guidance. ... Adjusted earnings per share of $1.12 beat the Zacks Consensus Estimate of $1.03. ... Solta Medical and Bausch + …

nasdaq.com

7%
OFF

Why Is Bausch (BHC) Down 11.7% Since Last Earnings Report?

2 weeks from now

Nov 29, 2024 · Adjusted earnings per share of $1.12 beat the Zacks Consensus Estimate of $1.03. ... Bausch + Lomb’s revenues increased 10% organically on a year-over-year basis, …

nasdaq.com

FAQs about Bausch + Lomb shares climb on earnings beat, raised outlook Coupon?

Why did Bausch & Lomb stock pop premarket Wednesday?

Bausch & Lomb’s stock popped premarket Wednesday after the vision care company beat profit estimates for the fourth quarter. This feature is powered by text-to-speech technology. Want to see it on more articles? ...

How much will Bausch & Lomb make in 2024?

The company is now expecting 2024 revenue of $4.600 billion to $4.700 billion, while FactSet is expecting $4.550 billion. See also: Bausch + Lomb to buy ‘dry eye’ treatment from Novartis in a $2.5 billion deal Revenue at the company’s vision care segment rose 6% in the quarter to $662 million. ...

How many times has Bausch & Lomb surpassed consensus EPS estimates?

Over the last four quarters, the company has surpassed consensus EPS estimates two times. Bausch + Lomb, which belongs to the Zacks Medical Services industry, posted revenues of $1.2 billion for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 2.54%. This compares to year-ago revenues of $1.01 billion. ...

How much did Bausch & Lomb make?

Revenues from Bausch + Lomb totaled $1.19 billion, up 19% year over year. The figure missed both the Zacks Consensus Estimate and our model estimate of $1.2 billion. Bausch + Lomb’s revenues increased 10% organically on a year-over-year basis, driven by growth across all business units. ...

Will Bausch Health sell its 88% stake in Bausch & Lomb?

The newspaper said that Bausch Health's four-year effort to spin off its 88% stake in Bausch + Lomb to shareholders has pivoted to seeking an outright sale. Net loss at Bausch Health in the quarter narrowed to $85 million, from a loss of $378 million a year earlier. On a per-share basis, this was a loss of 23 cents compared with a loss of $1.03. ...

Why did Bausch Health shares rise?

By Adriano Marchese Bausch Health shares rose Thursday morning after the company raised its full year outlook following a better-than-expected third-quarter performance. Shares traded over 11% higher in Toronto at 12.68 Canadian dollars ($9.12). ...